Some of the most expensive drugs in the country are derived from biotechnology. But there is no law or regulatory pathway at the Food and Drug Administration to allow for cheaper biotech drugs such as those derived from chemicals like cholesterol pills or arthritis tablets with which doctors and their patients have become so familiar. Kathleen Jaeger, president and chief executive officer of the Generic Pharmaceutical Association tells the Chicago Tribune's Bruce Japsen about the state of the debate over a pathway for cheaper generic biotech drugs.
advertisement
Are Cheaper Biotech Drugs Coming?
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Some of the most expensive drugs in the country are derived from biotechnology. But there is no law or regulatory pathway at the Food and Drug Administration to allow for cheaper biotech drugs such as those derived from chemicals like cholesterol pills or arthritis tablets with which doctors and their patients have become so familiar. Kathleen Jaeger, president and chief executive officer of the Generic Pharmaceutical Association tells the Chicago Tribune's Bruce Japsen about the state of the debate over a pathway for cheaper generic biotech drugs.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
MinuteCE®
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
0.75 credits
<p>Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?</p>
CME/CE
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
0.50 credits
<p>TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management</p>
MinuteCE®
Partnering with Patients: Building Effective Communication and Support in HF Care
0.75 credits
<p>Partnering with Patients: Building Effective Communication and Support in HF Care</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?